Ultromega

What it is

High-potency re-esterified triglyceride (rTG) omega-3 (EPA/DHA) softgels from sustainably sourced cold-water fish. Purified to IFOS/GOED standards for low oxidation and heavy metals. Up to ~70% better absorption than ethyl ester fish oils (Dyerberg 2010: rTG ~124%, EE ~73% relative to nTG=100%).

Why rTG matters (mechanism)

To concentrate EPA/DHA above ~30%, manufacturers crack natural triglycerides (nTG) into ethyl esters (EE) - fatty acids bonded to ethanol - then molecularly distill. Cheap products stop at EE (~73% absorption of nTG). Premium products re-esterify back to a glycerol backbone → rTG. Pancreatic lipase recognizes the triglyceride substrate, hydrolyzes cleanly, micelles, absorbs more completely. Ultromega is rTG; cheap fish oil is usually EE.

Why oxidation control matters: oxidized fish oil is pro-inflammatory. It defeats the purpose of supplementation. IFOS/GOED standards: Peroxide Value (PV) ≤5 meq/kg, p-Anisidine Value (AV) ≤20, TOTOX = 2×PV + AV ≤26 (GOED/Codex). IFOS 5-star products run TOTOX <13 (half cap) + heavy metal, PCB, dioxin, furan, PAH testing per batch with public certificates of analysis. Counsel patients to smell-test on opening; an IFOS-certified product should not smell rancid.

What it does

EPA/DHA function as substrates for specialized pro-resolving mediators (SPMs) - resolvins, protectins, maresins (Serhan, Harvard) - and compete with arachidonic acid for COX/LOX, shifting eicosanoids toward less-inflammatory 3-series prostaglandins + 5-series leukotrienes. Incorporated into phospholipid membranes (neural, retinal) modulating fluidity + signal transduction.

Used for

Cardiovascular support, low fish intake, training-induced inflammation (DOMS blunting), cognitive-longevity protocols, mood support (EPA-weighted, Sublette 2011 meta), triglyceride lowering (AHA Science Advisory).

Pairs well with

• Mitomax - cardiovascular + mitochondrial. EPA/DHA improve inner-mitochondrial-membrane fluidity; both lipophilic substrates benefit from fat co-ingestion. [Practitioner]
• KPV - anti-inflammatory dual-pathway. KPV blocks NF-κB transcription (acute suppression); EPA/DHA-derived SPMs drive active resolution. Complementary, not redundant. [Clinical mechanism]
• Thymogen Alpha 1 - CV + immune aging. [Practitioner]
• Methylene Blue - cognitive longevity (DHA concentrated in neuronal membranes; MB acts as alternative electron donor at ETC)
• Opticut - fat-loss + anti-inflammatory baseline
• Synerg Mag - common Haven CV/CNS baseline

Dosing

Haven recommended (label protocol)

• Take per Haven label, with food containing fat - single most important practical instruction
• Pancreatic lipase depends on bile acid + dietary fat for mixed-micelle formation. EE form absorption increases >9× with high-fat meal vs low-fat (Lawson & Hughes 1988). rTG is less food-dependent but still benefits. Take with dinner (typically highest-fat meal) or breakfast with ≥10 g fat.

Practitioner-directed [Practitioner]

• Functional medicine baseline: 2 g/day EPA+DHA with largest meal; titrate to Omega-3 Index ≥8% (OmegaQuant dried blood spot, 2×/yr)
• Cardiac-risk + elevated TG on statin: 4 g/day as 2 g BID with meals
• Indication-specific clinical-trial doses:

• Split if ≥2 g/day to reduce fishy reflux; split if >3 g/day
• Reflux mitigation: rTG, enteric-coated, frozen capsules (freezer storage delays gastric dissolution). Quality matters - oxidized fish oil produces more reflux. IFOS-certified low-TOTOX product (Ultromega) should produce minimal burping.
• Blood thinners: timing does NOT mitigate interaction (pharmacodynamic). Continue INR monitoring at warfarin initiation/dose change. Hold 5–7 days pre-elective surgery per surgical service.

Cautions / contraindications

• Atrial fibrillation signal - STRENGTH, OMEMI, Gencer 2021 meta-analysis show small but consistent dose-dependent increase in new-onset AF at 1–4 g/day. NNH ~100–200 over years at 4 g/day. Discuss with any patient with prior AF, structural heart disease, or high AF risk before high-dose. For 1–2 g/day longevity dosing, absolute increase is small.
• Blood thinners (warfarin, apixaban, rivaroxaban, dabigatran, clopidogrel, aspirin) - current evidence does not support clinically meaningful additive bleed at <3 g/day on stable warfarin. Continue INR monitoring at initiation/dose change. At >3 g/day, closer monitoring. Hold 5–7 days pre-elective surgery.
• Fish/shellfish allergy - marine oils may contain residual protein. IFOS-certified highly purified; algal DHA available as substitute (lacks EPA).
• Bleeding diatheses / thrombocytopenia - counsel; consider lower dose
• Oxidation check - smell test on opening; discard if rancid. Albert 2013 (Sci Rep) showed common OTC products had high oxidation.
• GI - reflux, fishy burps, loose stool at high doses (mitigations above)
• Diabetes - older concerns about LDL-C rise (DHA-heavy high dose) - generally clinically insignificant; check lipid panel
• Pregnancy - generally beneficial (DHA for fetal neurodevelopment). Avoid cod liver oil specifically (vitamin A teratogenicity).

Key studies & references

• Bhatt DL et al. 2019 - REDUCE-IT - 4 g/day icosapent ethyl in statin-treated TG 135–499 → 25% RRR in CV composite - NEJM - DOI 10.1056/NEJMoa1812792 (PMID 30415628). [Caveat] mineral oil placebo controversy; small AF signal.
• Nicholls SJ et al. 2020 - STRENGTH - ~4 g/day EPA+DHA carboxylic acid → no benefit vs corn oil; AF 2.2% vs 1.3% (p<0.05) - JAMA - PMID 33190147
• Manson JE et al. 2019 - VITAL - 1 g/day × 5.3 yr, n=25,871 → no primary benefit; secondary ~28% reduction in total MI; larger in low-fish-intake/Black subgroups - NEJM - PMID 30415637
• Yokoyama M et al. 2007 - JELIS - 1.8 g/day EPA + statin × 4.6 yr in 18,645 Japanese pts → 19% RRR major coronary events - Lancet - PMID 17398308
• Kalstad AA et al. 2021 - OMEMI - post-MI elderly, no MACE benefit; small AF signal - Circulation - PMID 33191772
• Gencer B et al. 2021 - AF meta-analysis: pooled dose-dependent AF risk increase - Circulation - PMID 34612056
• Dyerberg J et al. 2010 - rTG vs EE bioavailability - PMID 20638827
• Sublette ME et al. 2011 - EPA in depression meta-analysis, supplements with ≥60% EPA significantly antidepressant - J Clin Psychiatry - PMID 21939614
• Skulas-Ray AC et al. 2019 - AHA Science Advisory on omega-3 for hyperTG (4 g/day reduces TG 20–30%, up to 50%+ severe) - Circulation - PMID 31422671
• Asbell PA et al. 2018 - DREAM - dry eye, 3 g/day × 12 mo: no significant benefit vs olive oil - NEJM - PMID 29652551

---